Dr Natalie Staplin
|Tel||+44 (0)1865 743975|
Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences. She joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics. Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease. She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
Mafham MM. et al, (2018), Nephrol Dial Transplant, 33, 257 - 264
Impact of chronic kidney disease on household income
Morton RL. et al, (2017), Kidney International Reports
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
3C Study Collaborative Group None., (2017), Am J Transplant
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group None., (2017), Nephrol Dial Transplant, 32, 2043 - 2051
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Storey BC. et al, (2017), Kidney Int